MetaVia (MTVA) Stock Price, News & Analysis

Company Overview

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

Key Stats

• Today's Range: $0.81 to $2.10
• 50-Day Range: $0.81 to $1.84
• 52-Week Range: $0.81 to $5.30
• Volume: 24.18 million shs
• Average Volume: 378,076 shs
• Market Capitalization: $7.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Buy

MetaVia Stock Analysis - MarketRank™

MetaVia scored higher than 45% of companies evaluated by MarketBeat, and ranked 655th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

MetaVia has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

MetaVia has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for MetaVia are expected to grow in the coming year, from ($3.90) to ($1.64) per share.

Price to Book Value per Share Ratio

MetaVia has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for MTVA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MetaVia does not currently pay a dividend.

Dividend Growth

MetaVia does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for MTVA.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.93

News Sentiment

MetaVia has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for MetaVia this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for MTVA on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MetaVia insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.05% of the stock of MetaVia is held by insiders.

Percentage Held by Institutions

Only 1.37% of the stock of MetaVia is held by institutions.

MTVA Stock Analysis - Frequently Asked Questions

How have MTVA shares performed this year?

MetaVia's stock was trading at $2.03 at the start of the year. Since then, MTVA shares have decreased by 60.1% and is now trading at $0.81.
View the best growth stocks for 2025 here.

How do I buy shares of MetaVia?

Shares of MTVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 4/16/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MTVA
• CIK: 1638287
• Web: www.neurobopharma.com
• Phone: 857-702-9600
• Fax: 734-293-0444
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.00
• High Stock Price Target: $12.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +1,381.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-12,470,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -189.12%
• Return on Assets: -122.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.41
• Quick Ratio: 2.41

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.44 per share
• Price / Book: 0.24

Miscellaneous

• Outstanding Shares: 8,655,000
• Free Float: 8,526,000
• Market Cap: $7.01 million
• Optionable: N/A
• Beta: 0.22